APEX HEALTHCARE BHD
KLSE (MYR): AHEALTH (7090)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
2.57
Today's Change
0.00 (0.00%)
Day's Change
2.57 - 2.58
Trading Volume
16,300
Post a Comment
Market Buzz
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
2
3
4
save malaysia!
Visa-free travel to China extended for Malaysians to 30 days
5
6
Koon Yew Yin's Blog
CPO price is rising rapidly as shown by chart below - Koon Yew Yin
7
Axcapital's investment blog
KAB - Executing its way to a record quarter. Could more Petronas contracts be coming?
8
BFM Podcast
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
kcfan
1,881 posts
Posted by kcfan > 2012-08-08 23:44 | Report Abuse
AHEALTH future business potential by promising, the company actively expanding the earned rate higher brand pharmaceutical products, and more over the patent of drugs to expand generic drug positive support of the products, and the friendly drug control policy.
OSK Research bullish on the company's future earnings growth potential, its own brand products to higher revenue and lead to higher earn pieces, it's cough syrup (accounting for the 2011 financial annual turnover of 5%) and cardiovascular drugs The product sells well, the benefit over the patent of drugs, as well as positive impact from friendly control policy change and positive support.
The company also has its own brand of pharmaceutical products, the third party's Yibo Shi Pharmacy also sells brand-name pharmaceuticals. 30% of turnover from own brand products, and the remaining 70 percent is the third-party pharmaceutical products. Expected in 2011-2016, $ 67 billion worth of drugs over the patent period, further expansion of generic drug products in the market space.
The company plans to expand its brand pharmaceutical products to enhance the earning increase (about 40-50%), compare third-party products is about 10%. It is currently R & D Avex, Avo, Kaps and other brand product line. Its Malacca plant is nearly fully operational, but also increase another production shift to increase production.
The company is one more than the patents of drugs manufacturers and third-party drug distributors involved in operating areas, including Singapore, Malaysia, Vietnam and Indonesia.
2011 to a market survey, in 2005, patented drugs accounted for 70% of the global pharmaceutical overhead, but to the 2015 material will fall to the level of 53%, because more drug patent of overdue due. The same time, the amount of overhead of the generic drugs from 20% in 2005 to 2015, Young rose to the level of 39%.
The company's turnover for the past eight years compound annual growth rate reached 9.9 percent compound annual growth rate of the company's future earnings growth is expected to reach 16.6%. (Sin Chew Jit Poh / Finance)